Table 1. In silico and in vitro characterization of nuciferine.
| SEA Predictions (in order of confidence) | In Vitro Affinity (nM) | Functional EC50 (nM) | Function Type |
|---|---|---|---|
| Radioligand used | |||
| D1 (5.4e-32) | 752 [3H]SCH23390 | ||
| D2 (1.6e-25) | 515 [3H]N-methyl Spiperone | 65.07 | Partial agonist |
| D3 (1.3e-12) | 741 [3H]N-methyl Spiperone | ||
| D5 (5.0e-13) | (neg) [3H]SCH23390 | 2600 | Partial agonist, ~50% |
| VMAT2 (2.1e-13) | NA | ||
| SK Channel (3.8e-11) | NA | ||
| 5-HT1A (1.2e-11) | 77 [3H]WAY100635 | 3230 | Agonist |
| 5-HT5B (1.6e-7) | |||
| 5-HT7 (4.1e-4) | 49.8 [3H]LSD | 150 | Inverse agonist |
| 5-HT2A (4.1e-6) | 312 [3H]Ketanserin | 478 | Antagonist |
| Unpredicted Hits | |||
| 5-HT2B | 41 [3H]LSD | 1000 | Antagonist |
| 5-HT2C | 60.5 [3H]Mesulergine | 131 | Antagonist |
| 5-HT6 | 268 [3H]LSD | 700 | Partial agonist, 17.3% |
| D4 | 1387 [3H]N-methyl Spiperone | 2000 | agonist |
Receptor targets are listed with their respective SEA prediction value (if available), followed by their competition binding affinity value (if available), followed by their functional EC50 value (if available) and the corresponding function type.
Information about cell lines for all assays can be found at http://pdsp.med.unc.edu/pdspw/binding.php.